Advancements in Basal Insulin: Tailoring Treatment to Patient Needs
Type: Accredited Symposia
Thursday May 10 6:00pm to 7:00pm Location: Symposia B
Basal insulin remains one of the most effective treatments for type 2 diabetes, resulting from its high potency and lack of a dose ceiling. But, as patients and healthcare providers will affirm, it has long been a balancing act between the highs and lows.
Over the course of this session, participants will explore the key barriers to insulin therapy, the latest basal insulin options, and strategies to individualize insulin therapy in type 2 diabetes. Furthermore, participants will use case-based discussion alongside a workbook to apply new knowledge, and reflect on how the latest insulin options can be integrated into clinical practice to improve patient care.
Recognize the role of basal insulin therapy in the T2DM treatment continuum.
Identify and overcome barriers to insulin initiation and optimization from the patient and physician perspective, including hypoglycemia.
Differentiate basal insulin options, with a focus on the newer basal insulins.
Individualize basal insulin treatment based on patient characteristics and insulin profiles.
This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College’s Ontario Chapter.
This program was supported in part by an educational grant from Novo Nordisk.
Harpreet Bajaj MD, MPH, ECNU, FACE Harpreet Singh Bajaj started his Endocrinology specialty clinical practice in Brampton in 2009 after completing his clinical fellowship at the Cleveland Clinic (Ohio, USA). Dr. Bajaj’s medical education was at Maulana Azad Medical College (New Delhi, India), following which he attained a Masters of Public Health (MPH, major in Epidemiology) at State University of New York in Albany (New York, USA).
Dr. Bajaj is a Research Associate at Mount Sinai Hospital, Toronto and an adjunct lecturer at McMaster University. He has co-authored publications in key medical journals in the fields of diabetes, obesity and cardiovascular risk assessment. His major interest lies in translational research focused on “real-life” practical approaches to improve standards of clinical practice for diabetes and cardiovascular risk factors.
He volunteers with numerous community public health as well as media programs with the intent of raising public awareness on diabetes prevention and treatment, with a specific focus on the South Asian origin population in Canada. He is the founder of STOP Diabetes Foundation, a registered charitable organization, working to reduce the burden of diabetes in Peel region of Ontario.
Dr. Bajaj serves Diabetes Canada (formerly CDA) as a co-chair of the Communications and Marketing portfolio within the professional section national executive, as a national consultant editor for the Canadian Journal for Diabetes and as an expert committee member for the 2018 Clinical Practice Guidelines.